Last reviewed · How we verify
NCT04067986
Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer
Status unknown
Phase 1, PHASE2
Last updated 29 September 2020
What this trial tests
Phase 1, PHASE2 trial testing Camrelizumab in Colorectal Cancer Recurrent in 62 participants. Status unknown.
Timeline
20 August 2019
Primary endpoint
23 September 2020
23 September 2020
31 October 2021
Quick facts
| Lead sponsor | Zhongshan Hospital Xiamen University |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 62 |
| Start date | 20 August 2019 |
| Primary completion | 23 September 2020 |
| Estimated completion | 31 October 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Camrelizumab — full drug profile →
- Apatinib (Apatinib) — full drug profile →
Conditions studied
- Colorectal Cancer Recurrent — all drugs for Colorectal Cancer Recurrent →
Sponsor
Zhongshan Hospital Xiamen University
Who can join
Adults 18 to 75, any sex, with Colorectal Cancer Recurrent. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The efficacy and safety of the use of Camrelizumab combined with Apatinib
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications.
Zhong X, He X, Wang Y, Hu Z, et al · · 2022 · cited 223× · PMID 36319992 · DOI 10.1186/s13045-022-01358-5 -
Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond.
Al Bitar S, El-Sabban M, Doughan S, Abou-Kheir W. · · 2023 · cited 53× · PMID 36998426 · DOI 10.3748/wjg.v29.i9.1395 -
Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer.
Cimino SK, Eng C. · · 2020 · cited 5× · PMID 33204182 · DOI 10.2147/jep.s259287 -
Immunotherapy combined with apatinib in the treatment of advanced or metastatic gastric/gastroesophageal tumors: a systematic review and meta-analysis.
Wang J, Lin J, Wang R, Tong T, et al · · 2024 · cited 3× · PMID 38760737 · DOI 10.1186/s12885-024-12340-4 -
State-of-the-Art of Monoclonal Antibodies for the Treatment of Gastric Cancer.
Basile D, Simionato F, Cappetta A, Garattini SK, et al · · 2021 · cited 3× · PMID 34764633 · DOI 10.2147/btt.s290323 -
Apatinib enhances anti-PD-1 efficacy by inhibiting Exo70-mediated exosome secretion in pMMR/MSS colorectal cancer.
Zhao L, Gao C, Qiao X, Lou F, et al · · 2026 · PMID 42215704 · DOI 10.1038/s41698-026-01518-7
Verify or expand the search:
- PubMed search for NCT04067986
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Camrelizumab
Trials testing the same drug.
- NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
- NCT07466901 — A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Rad · NA · not yet recruiting
- NCT07527026 — A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant T · Phase 2 · recruiting
- NCT07266350 — A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for th · not yet recruiting
Other recruiting trials for Colorectal Cancer Recurrent
Currently open trials in the same condition.
- NCT06992648 — Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal · Phase 3 · recruiting
- NCT06769828 — Ga-68-FAPI-46 PET for CRC Recurrence Detection in Elevated CEA · NA · recruiting
- NCT07226115 — Splicing-based Predictive Learning for Individual Chemotherapy Evaluation in Colorectal Cancer · recruiting
- NCT06229340 — Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations · Phase 2 · recruiting
- NCT06957626 — Development and Validation of Microbiota and Metabolite-based Prediction Model for Recurrence of High-risk Colorectal Po · recruiting
Other Zhongshan Hospital Xiamen University trials
Trials by the same sponsor.
- NCT07212569 — Analysis of Differences in Small Intestinal Microbiota Structure and Metabolites Between Patients With Irritable Bowel S · not yet recruiting
- NCT07045883 — Mechanism and Application of Vitamin D in Idiopathic Sudden Sensorineural Hearing Loss · NA · active not recruiting
- NCT06530069 — Exploring the Risk Factors of Otomycosis: A Case-Control Study · recruiting
- NCT06431542 — Efficacy of Self Vs. Physician Application of Triamcinolone-Econazole in Otomycosis · Phase 4 · completed
- NCT05274191 — An Exploratory Basket Study of Pyrotinib Maleate Tablets in HER2 Mutated or Amplified of Metastatic Solid Tumors · Phase 2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04067986 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhongshan Hospital Xiamen University
- Last refreshed: 29 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04067986.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing